Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580  by Eyers, Patrick A. et al.
Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38
to validate the in vivo speci¢city of SB 203580
Patrick A. Eyersa, Paul van den IJsselb, Roy A. Quinlanb, Michel Goedertc, Philip Cohena;*
aMRC Protein Phosphorylation Unit, MSI/WTB Complex, University of Dundee, Dow Street, Dundee DD1 5EH, UK
bDepartment of Biochemistry, MSI/WTB Complex, University of Dundee, Dow Street, Dundee DD1 5EH, UK
cMRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, UK
Received 6 April 1999
Abstract Stress-activated protein kinase 2a, also called p38, is
inhibited by SB 203580 and this drug has been used widely to
implicate this enzyme in the regulation of many physiological
processes. Here, we introduce a novel method of general
application, which can be used to establish whether the effects
of SB 203580 are mediated via inhibition of stress-activated
protein kinase 2a/p38 or whether they result from ‘non-specific’
effects. Four events thought to occur upon activation of stress-
activated protein kinase 2a/p38 have been established unequiv-
ocally. These are the activation of mitogen-activated protein
kinase-activated protein kinase-2 and mitogen- and stress-
activated protein kinase-1 and the phosphorylation of their
presumed substrates, heat shock protein 27 and the transcription
factor cyclic AMP response element binding protein, respec-
tively. In contrast, the SB 203580-induced activation of c-Raf is
independent of stress-activated protein kinase 2a/p38 inhibition.
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1. Introduction
Nearly all aspects of cell life are controlled by the reversible
phosphorylation of proteins. Approximately one third of
mammalian proteins contain covalently bound phosphate
and protein kinases represent the largest single family of en-
zymes in the human genome, with perhaps 2000 members.
Assuming that 100 000 proteins are encoded by the human
genome, an ‘average’ protein kinase should phosphorylate
about 15 substrates in vivo. A major challenge is therefore
to identify unambiguously all the physiological substrates of
each protein kinase. One strategy to address this problem
would be to develop small cell-permeant compounds that
are speci¢c inhibitors of protein kinases and to examine their
e¡ects on intact cells and tissues. The recent discovery of
compounds with the requisite speci¢city establishes this as a
valid approach with an enormous potential [1,2].
One such compound is SB 203580, a member of a class of
pyridinyl imidazoles that were originally shown to suppress
the bacterial lipopolysaccharide (LPS)-induced production of
tumour necrosis factorK (TNFK) and to be e¡ective in animal
models of chronic in£ammatory disease [3,4]. The presumed
target of SB 203580, initially identi¢ed as a binding protein
[3], is a mitogen-activated protein kinase (MAPK) family
member termed stress-activated protein kinase 2a (SAPK2a)
or p38. Subsequently, SB 203580 was shown to be highly
speci¢c for SAPK2a/p38 [5], as other MAPK family members
(as well as many other protein kinases) were insensitive to this
drug [5,6]. For this reason, SB 203580 has been used in hun-
dreds of publications to implicate SAPK2a/p38 in a wide
range of physiological processes with the implicit assumption
that the drug was extremely speci¢c for SAPK2/p38 (reviewed
in [1]). However, it has emerged that there are other SB
203580-sensitive enzymes, which include cyclo-oxygenases 1
and 2 [7] and the protein kinase Raf [8,9]. These ¢ndings
now question which of the reported e¡ects of SB 203580
can be attributed to inhibition of SAPK2a/p38 and which
are due to the ‘non-speci¢c’ inhibition of other enzymes.
The co-crystallisation of SAPK2a/p38 in complex with pyr-
idinyl imidazoles related to SB 203580 [10,11] pinpointed Thr-
106 as being critical for inhibition by SB 203580. As pre-
dicted, mutation of this residue to amino acids with larger
side chains was shown to render SAPK2a/p38 insensitive to
SB 203580 [10,12,13]. By implication, the insensitivity of other
MAPK family members to SB 203580 was due to amino acid
residues with larger side chains at this position. Indeed, mu-
tation of these to smaller residues (e.g. threonine) then ren-
dered these kinases sensitive to the drug [12^14]. In this paper,
we inducibly express a drug-resistant mutant of SAPK2a/p38
and exploit it to investigate whether some of its putative tar-
gets are bona ¢de substrates in intact cells.
2. Materials and methods
2.1. Antibodies
Antibodies that recognise human HSP27 only when phosphorylated
at Ser-15 and Ser-78 were raised in sheep at the Scottish Antibody
Production Unit (Carluke, UK). The peptides LLRGPS*15WDPFRC
and YSRALS*78RQLSSC (phosphorylated at the serines equivalent
to Ser-15 and Ser-78, respectively) were coupled via their C-terminal
cysteines to keyhole limpet haemocyanin using the cross linking agent
sulphosuccinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate
(Calbiochem, Nottingham, UK) according to the manufacturer’s in-
structions. The antisera were puri¢ed by a⁄nity chromatography on
the relevant phosphopeptide-agarose columns followed by chromatog-
raphy on the relevant dephosphopeptide-agarose. The speci¢city of
these antibodies was established by the ¢nding that they did not
recognise bacterially expressed HSP27 and only recognised HSP27
in lysates from U373 cells that had been exposed to chemical stress
(sodium arsenite). A SAPK2a/p38-speci¢c antibody raised in sheep
against the C-terminal sequence (ISFVPPPLDQEEMES) of the hu-
man enzyme was a⁄nity-puri¢ed in a similar manner. Polyclonal anti-
sera that recognise phosphorylated and dephosphorylated HSP27
equally well and an antibody that recognises the Ser-133 phospho-
rylated form of the cyclic AMP response element binding protein
(CREB) were purchased from UBI (Lake Placid, NY, USA). A mono-
clonal antibody 12CA5 that recognises the haemagglutinin epitope
was obtained from Boehringer (Lewes, UK). A⁄nity-puri¢ed antisera
to rabbit, mouse and sheep IgG were purchased from Pierce and used
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at dilutions of 1:10 000. Immunoreactive protein was detected by the
enhanced chemiluminescence technique (Amersham International,
UK).
2.2. Construction of stable 293 cell lines inducibly expressing wild-type
SAPK2a/p38 or an SB 203580-insensitive mutant
The procedure was carried out using reagents from Invitrogen
(Leek, The Netherlands) according to the procedures recommended
by the manufacturer. The human SAPK2a/p38 sequence (CSBP2 var-
iant [3]) including a haemagglutinin tag at the N-terminus was sub-
cloned into the BamHI site of the pIND vector [15]. This construct
expresses SAPK2a/p38 only in the presence of ponasterone A, an
analogue of the insect hormone ecdysone. A drug-resistant mutant
(DR-SAPK2a/p38), insensitive to SB 203580, was made by changing
the residues Thr-106, His-107 and Leu-108 to Met, Pro and Phe,
respectively, using the quick change PCR mutagenesis kit (Stratagene,
Cambridge, UK). Constructs were sequenced to verify that the muta-
genesis was successful. Human embryonic kidney 293 cells stably ex-
pressing the ecdysone receptor subunits were cultured in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) in the presence of 10% (by vol-
ume) foetal calf serum, 2 mM glutamine, 100 IU/ml penicillin, 0.1 mg/
ml streptomycin and 0.4 mg/ml zeocin. Wild-type (WT) SAPK2a/p38
or DR-SAPK2a/p38 were transiently transfected into the cells and
then selected for, using 1 mg/ml of the antibiotic G418 (Gibco
BRL, Paisley, UK) for 14 days to generate cells that inducibly express
these enzymes only after stimulation with ponasterone A.
2.3. Cell stimulation and analysis of downstream targets of
SAPK2a/p38
Cells were stimulated with 10 WM ponasterone A for 23 h followed
by a 1 h treatment with SB 203580. They were then exposed to either
anisomycin (10 Wg/ml) for 30 min or to UV-C radiation (200 J/m2)
and incubated for 30 min before lysis as in [16]. The lysates were
centrifuged (13 000Ug, 10 min), the supernatants removed and the
nuclear pellets extracted in 1% (w/v) SDS. MAP kinase-activated pro-
tein kinase-2 (MAPKAP-K2) [17] or mitogen- and stress-activated
protein kinase-1 (MSK1) [18] were immunoprecipitated from the
supernatants and assayed as described [18]. The SDS-extracted pellets
were electrophoresed on 10% SDS/polyacrylamide gels, transferred to
nitrocellulose and immunoblotted with the anti-phospho-CREB anti-
body. A plasmid encoding human HSP27 (pcDNA3.1) was transiently
transfected into the 293 cells 24 h before induction with ponasterone
A and analysed by immunoblotting the supernatants using anti-
HSP27 antibodies (Section 2.1).
3. Results
3.1. SB 203580-insensitive forms of SAPK2a/p38
The mutation of Thr-106, His-107 and Leu-108 to Met, Pro
and Phe, respectively, (i.e. to the residues present in the re-
lated, but SB 203580-insensitive SAPK3 and SAPK4) is re-
ported to make SAPK2a/p38 even more resistant to SB
203580 than the single mutation of Thr-106 to Met [13].
The triple mutant, hereafter called DR-SAPK2a/p38, was
used in the present study but, in our hands, it was found to
be no more resistant to SB 203580 than the Thr-106-Met
mutant (Fig. 1A).
3.2. Identi¢cation of stable cell lines that inducibly express
SAPK2a/p38
Cells that stably express transfected HA-tagged pIND SAP-
K2a/p38 contain a gene that confers resistance to the anti-
biotic G418, whereas untransfected cells are killed [16]. After
14 days growth in 1.0 mg/ml G418, 20 colonies were picked,
further cultured in the presence of 0.5 mg/ml G418 and tested
for ponasterone A-dependent induction of SAPK2a/p38.
About half of these colonies showed an inducible SAPK2a/
p38 protein. One cell line expressing WT-SAPK2a/p38 and
one expressing the drug-resistant mutant DR-SAPK2a/p38
(Fig. 1B) were chosen for further study. After stimulation
with 10 WM ponasterone A, both cell lines overexpressed the
Fig. 1. Characterisation of the SB 203580-sensitivity of WT-SAPK2a/p38 and DR-SAPK2a/p38 and their inducible expression in 293 cells.
A: Inhibition by SB 203580 of WT-SAPK2a/p38 (open circles), the triple mutant DR-SAPK2a/p38 in which Thr-106, His-107 and Leu-108
have been mutated to Met, Pro and Phe, respectively (closed circles), and the single mutant Thr-106-Met SAPK2a/p38 (closed triangles). Each
enzyme was expressed as a GST fusion protein in Escherichia coli and assayed using myelin basic protein as substrate [12]. B: 293 cells stably
expressing DNA encoding HA-tagged WT-SAPK2a/p38 or DR-SAPK2a/p38 were stimulated for 24 h with the indicated concentrations of po-
nasterone A. Aliquots of the cell lysates were denatured in SDS and subjected to polyacrylamide gel electrophoresis. After transfer to nitro-
cellulose, the membranes were immunoblotted with an anti-HA antibody. The positions of WT-SAPK2a/p38 and DR-SAPK2a/p38, which
migrated slightly faster than the ovalbumin marker (43 kDa), are indicated. No HA-SAPK2a/p38 was detected in the absence of ponasterone
A. The cross-reactive band present in all lanes, and which migrates slightly slower than ovalbumin, is an unknown protein recognised non-
speci¢cally by the HA antibody which demonstrates equal loading of the samples.
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HA-tagged enzymes approximately 5-fold as compared to the
endogenous WT enzyme (data not shown).
3.3. The activation of MAPKAP-K2 and the phosphorylation
of HSP27 are no longer sensitive to SB 203580 in cells
expressing DR-SAPK2a/p38
The availability of a cell line capable of overexpressing DR-
SAPK2a/p38 provided an opportunity to establish whether
putative downstream targets identi¢ed in earlier studies were
indeed physiological substrates. One such enzyme is MAP-
KAP-K2, which is activated by SAPK2a/p38 in vitro [19]
and whose activation by cell damaging agents and other stim-
uli is prevented by SB 203580 ([5], reviewed in [1]). Before
induction with ponasterone A, cells stably transfected with
WT-SAPK2a/p38 or DR-SAPK2a/p38 behaved like untrans-
fected 293 cells, in that the endogenous MAPKAP-K2 was
essentially inactive until exposed to UV-C radiation. As ex-
pected, the UV-induced activation of the endogenous MAP-
KAP-K2 was suppressed by SB 203580 with an IC50 of 100
nM (Fig. 2A). After induction by ponasterone A, the basal
level of MAPKAP-K2 was not elevated nor was the activity
attained after exposure to UV-C radiation, despite the 5-fold
overexpression of SAPK2a/p38 (Fig. 2B). In contrast, the ac-
tivation of MAPKAP-K2 in cells overexpressing DR-SAP-
K2a/p38 was no longer suppressed signi¢cantly by SB
203580, whereas the sensitivity of the cells overexpressing
WT-SAPK2a/p38 (Fig. 2B) was the same as before induction
(Fig. 2A).
A putative physiological substrate for MAPKAP-K2 is
HSP27. It is phosphorylated by MAPKAP-K2 in vitro at
the same residues that become phosphorylated in response
to signals that activate SAPK2a/p38 ([20], reviewed in [1])
and these phosphorylations are suppressed by SB 203580 [5].
The results obtained in the present study establish that HSP27
is indeed a ‘downstream component’ of the SAPK2a/p38
pathway, because its phosphorylation at Ser-15 (Fig. 3) and
Ser-78 (data not shown), induced by either UV-C radiation or
the protein synthesis inhibitor anisomycin, is no longer sup-
Fig. 2. SB 203580 no longer blocks the activation of MAPKAP-K2 in 293 cells expressing DR-SAPK2a/p38. A: Cells not stimulated with po-
nasterone A were pre-incubated for 1 h with the indicated concentrations of SB 203580 and then exposed to UV-C radiation. After cell lysis,
MAPKAP-K2 was immunoprecipitated from 50 Wg of lysate and assayed [16]. Units of MAPKAP-K2 are de¢ned in [16]. The open bars show
cells stably transfected with WT-SAPK2a/p38 and the closed bars cells stably transfected with DR-SAPK2a/p38. B: The same as A, except that
the cells were ¢rst stimulated for 23 h with 10 WM ponasterone A prior to incubation with SB 203580 and exposure to UV-C radiation. The
data shown are the mean þ S.E.M. for three separate ponasterone A inductions. All assays were carried out in triplicate.
Fig. 3. SB 203580 no longer blocks the phosphorylation of HSP27 in 293 cells expressing DR-SAPK2a/p38. Cells stably expressing DNA en-
coding HA-tagged WT-SAPK2a/p38 or DR-SAPK2a/p38 were transiently transfected with a plasmid encoding human HSP27. After 24 h, the
cells were stimulated for 23 h with 10 WM ponasterone A, then incubated for 1 h with the indicated concentrations of SB 203580. After expo-
sure to either UV-C radiation or anisomycin (Section 2.3), the cells were lysed and the extent of phosphorylation of HSP27 was measured by
immunoblotting with a phospho-speci¢c antibody that only recognises HSP27 phosphorylated at Ser-15. Similar results were obtained with a
second phospho-speci¢c antibody that only recognises the Ser-78-phosphorylated form of HSP27 (not shown). The lysates were also blotted
with an anti-HSP27 antibody that recognises both phosphorylated and dephosphorylated HSP27, further establishing the speci¢city of the phos-
pho-speci¢c antibodies. An HA antibody (that recognises the induced SAPK2a/p38) was used to show equivalent expression in all lysates. Simi-
lar results were obtained in two separate experiments.
FEBS 22013 18-5-99
P.A. Eyers et al./FEBS Letters 451 (1999) 191^196 193
pressed signi¢cantly by SB 203580 in cells overexpressing DR-
SAPK2a/p38.
3.4. The activation of MSK1 and the phosphorylation of CREB
are no longer sensitive to SB 203580 in cells expressing
DR-SAPK2a/p38
MSK1 is a recently identi¢ed protein kinase that can be
activated in response to either growth factors/phorbol esters
or cell damaging agents/pro-in£ammatory cytokines. The ac-
tivation of MSK1 by growth factors and phorbol esters ap-
pears to be mediated via the classical MAP kinase cascade
because it is prevented by a speci¢c inhibitor of this pathway
(the drug PD 98059). Activation of MSK1 by cell damaging
stimuli and pro-in£ammatory cytokines may be mediated by
SAPK2a/p38, because it is prevented by SB 203580 [18]. Con-
sistent with this hypothesis, MSK1 can be activated in vitro
by either MAPK2/ERK2 or SAPK2a/p38 [18]. The results
presented in Fig. 4 establish that the activation of MSK1 in
response to UV-C radiation is mediated by SAPK2a/p38, be-
cause it is hardly suppressed by SB 203580 in cells over-
expressing DR-SAPK2a/p38. In contrast, SB 203580 blocks
UV-induced MSK1 activation in cells overexpressing WT-
SAPK2a/p38 (Fig. 4).
MSK1 is predominantly localised to the nucleus and one of
its putative physiological substrates is the transcription factor
CREB, which it phosphorylates at Ser-133 with an extremely
low Km value in vitro. Ser-133 becomes phosphorylated in
response to signals that activate SAPK2a/p38 [18] and phos-
phorylation is suppressed by SB 203580 [21]. Here, we estab-
lish that CREB and the closely related activating transcription
factor 1 (ATF1) do indeed lie ‘downstream’ of SAPK2a/p38.
This is because their phosphorylation can be induced by either
UV-C radiation (Fig. 5) or the protein synthesis inhibitor
anisomycin (data not shown). Their phosphorylation is also
not suppressed signi¢cantly by SB 203580 in cells overexpress-
ing DR-SAPK2a/p38. In contrast, CREB and ATF1 phos-
phorylation remain sensitive to the drug in cells overexpress-
ing WT-SAPK2a/p38 (Fig. 5).
3.5. The activation of c-Raf by SB 203580 is not mediated by
inhibition of SAPK2a/p38
The proto-oncogene c-Raf possesses a threonine residue at
the position equivalent to Thr-106 of SAPK2a/p38 and, for
this reason, is inhibited by SB 203580. The IC50 in vitro (2 WM
when assayed at 0.1 mM ATP) is 40-fold higher than for
human SAPK2a/p38 assayed under the same conditions [8].
Remarkably, however, incubation of mammalian cells with
Fig. 4. SB 203580 no longer blocks the activation of MSK1 in 293
cells expressing DR-SAPK2a/p38. Experimental conditions were as
in Fig. 2B, except that MSK1 was immunoprecipitated from 500 Wg
of cell lysate and assayed as in [18]. Units of MSK1 activity are de-
¢ned in [18]. The open and closed bars show cells stably transfected
with WT-SAPK2a/p38 and DR-SAPK2a/p38, respectively. The data
shown are the mean þ S.E.M. for three separate ponasterone A in-
ductions. All assays were carried out in triplicate.
Fig. 5. SB 203580 no longer blocks the phosphorylation of CREB
at Ser-133 or ATF1 at Ser-63 in 293 cells expressing DR-SAPK2a/
p38. The experiment was carried out as in Fig. 3, except that the
phosphorylation of CREB and ATF1 was visualised by immuno-
blotting using SDS-extracted nuclear extracts and a phospho-speci¢c
antibody that recognises Ser-133-phosphorylated CREB and Ser-63-
phosphorylated ATF1. 10 Wg of nuclear lysate protein was loaded
per gel lane and the data shown are from one experiment performed
in duplicate. Similar results were obtained in several other experi-
ments.
Fig. 6. SB 203580 activates c-Raf in cells expressing either WT-SAP-
K2a/p38 or DR-SAPK2a/p38. Cells were serum-starved for 23 h in
the presence of 10 WM ponasterone A, then incubated for 30 min
with the indicated concentrations of SB 203580 followed by a 30
min incubation with 10 Wg/ml anisomycin to activate MAPKAP-K2.
Anisomycin does not induce any activation of c-Raf. The cells were
lysed, c-Raf immunoprecipitated from 0.1 mg lysate protein and as-
sayed as in [25]. The open circles show c-Raf activation in cells
overexpressing WT-SAPK2a/p38 and the closed circles show Raf ac-
tivation in cells overexpressing DR-SAPK2a/p38. The results are
presented as fold activation relative to control cells incubated in the
absence of SB 203580 and are shown þ S.E.M. for two dishes of
cells each assayed in triplicate. Similar results were obtained in two
separate experiments.
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SB 203580 triggers a 25-fold activation of c-Raf when it is
assayed after immunoprecipitation from cell lysates in the
absence of SB 203580 [8,9]. The results presented in Fig. 6
demonstrate that the activation of c-Raf triggered by SB
203580 does not result from inhibition of SAPK2a/p38, be-
cause the same activation still occurs in cells overexpressing
DR-SAPK2a/p38. In contrast, the anisomycin-induced activa-
tion of MAPKAP-K2 in the same cell lysates was not sup-
pressed signi¢cantly by any concentration of SB 203580 in the
cells overexpressing DR-SAPK2a/p38 (data not shown).
4. Discussion
Although SB 203580 is one of the most speci¢c protein
kinase inhibitors to have been developed, it is not quite as
speci¢c as previously supposed. Nearly all human protein kin-
ases are insensitive to SB 203580, because they possess a side
chain larger than threonine at the position equivalent to Thr-
106. A few other protein kinases possess threonine or serine at
this position (although none have glycine or alanine). Those
that have been tested (the type-I and type-II TGFL receptors,
the tyrosine kinase lck and the proto-oncogene c-Raf) are all
inhibited by SB 203580, albeit more weakly than SAPK2a/p38
[8,12]. Inhibition of the TGFL receptors is caused by the pres-
ence of Ser and Thr at the relevant position, because their
mutation to Met abolishes sensitivity to SB 203580 [12]. In
our standard in vitro assay, conducted at 0.1 mM ATP, the
type-I and type-II TGFL receptors and lck are inhibited by SB
203580 with IC50 values of 20, 40 and 25 WM, respectively,
400^800-fold higher than the IC50 for human SAPK2a/p38.
Since inhibition by SB 203580 is competitive with respect to
ATP, it is most unlikely that (at 10 WM) this drug will inhibit
these protein kinases in the intracellular milieu, where mM
concentrations of ATP are present.
In contrast to the TGFL receptors and lck, c-Raf is inhib-
ited by SB 203580 with an IC50 of 2 WM in vitro [8], only 40-
fold higher than SAPK2a/p38 and only 4-fold higher than
SAPK2b/p38L2 [12]. However, paradoxically, 10 WM SB
203580 induces a huge (25-fold) activation of c-Raf (measured
in the absence of SB 203580) [8,9]. These observations suggest
that cells contain a feedback loop by which Raf suppresses its
own activity, perhaps explaining why SB 203580 does not
a¡ect signalling through the classical growth factor-stimulated
MAP kinase cascade in cells. Alternatively, and in contrast to
current thinking, c-Raf activity may not be rate limiting for
activation of the Ras-MAP kinase cascade. These unexpected
¢ndings are fortuitous, otherwise, SB 203580 would have little
use as a speci¢c signalling inhibitor!
It has also been reported that two isoforms of SAPK1/
JNK, another MAP kinase family member, show some sensi-
tivity to SB 203580, even though they contain a large residue
(Met) at the position equivalent to Thr-106 of SAPK2a/p38
[22]. In our standard in vitro assay, SAPK1a/JNK2K2 and
SAPK1b/JNK3K1 were inhibited by SB 203580 with IC50 val-
ues of 20^40 WM and SAPK1b/JNK3K2 with an IC50 value of
3 WM. These are 50^500-fold higher than the IC50 for SAP-
K2a/p38 measured under the same conditions. Moreover, in
the ¢broblast cell lines that we have studied [23,24] and in 293
cells (P.A.E. unpublished work), the phosphorylation of c-Jun
and ATF2, two putative SAPK1/JNK substrates, are unaf-
fected by exposure of the cells to 10 WM SB 203580.
It is clear from the studies cited above that it would be a
great advantage to know whether a reported e¡ect of SB
203580 is mediated via inhibition of SAPK2a/p38 or another
enzyme. After all, other protein kinases and enzymes may
exist that are potently inhibited by SB 203580. In this paper,
we introduce a simple method for establishing whether the
cellular e¡ects of SB 203580 are mediated by inhibition of
SAPK2a/p38 and have exploited this to prove that MAP-
KAP-K2 and MSK1, and their presumed substrates HSP27
and CREB/ATF1, lie ‘downstream’ of SAPK2a/p38. In con-
trast, the activation of c-Raf induced by SB 203580 is inde-
pendent of the inhibition of SAPK2a/p38 and presumably
caused by the binding of SB 203580 to c-Raf itself. Our results
also imply that none of these four proteins are speci¢c sub-
strates for the closely related SAPK2b/p38L2, the only other
MAP kinase family member inhibited by SB 203580. Other-
wise, the overexpression of DR-SAPK2a/p38 would not have
a¡ected the sensitivity of these four proteins to SB 203580.
Although DR-SAPK2a/p38 was overexpressed compared to
the endogenous enzyme, no activation occurred until it was
exposed to a cell damaging agent and, even then, the activity
of a downstream reporter (MAPKAP-K2) was only increased
to the same extent as in uninduced cells. To our knowledge,
this is the ¢rst time that a drug-insensitive protein kinase (or
perhaps any enzyme) has been used in this way for the pur-
pose of drug target validation and this approach should be
generally applicable to the study of other protein kinases. In
the future, it might be possible to improve this method by
generating mice in which a drug-insensitive protein kinase
replaces the WT enzyme so that possible interference caused
by the presence of the endogenous WT enzyme is eliminated.
Adenoviral vectors and other methods with the potential for
quantitative transfection of mammalian cells could be ex-
ploited to express drug-insensitive protein kinases in primary
cells and tissues, as opposed to just transformed cell lines.
The methodology described in this paper could also be ex-
ploited in a further way to help elucidate the physiological
roles of other MAP kinase family members for which suitable
inhibitors have not yet been identi¢ed. Thus, we and others
have been able to confer SB 203580-sensitivity to other MAP
kinases by mutation of the relevant residue from Met/Gln to
Thr or a smaller residue [10,12^14]. Indeed, mutation to Ala
converts SAPK1/JNK1, SAPK3/p38Q and SAPK4/p38N to
forms that are as sensitive or even more sensitive to SB
203580 than human WT-SAPK2a/p38 [12]. In principle, it
should be possible, using the system described here, to induc-
ibly express these mutant enzymes in mammalian cells and to
identify their physiological substrates by ¢nding which protein
phosphorylation events are suppressed by SB 203580 that
were previously resistant to this drug. In this way, SB
203580 could be used to elucidate the physiological roles of
several MAP kinase family members.
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